Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Alkermes begins pivotal program for ALKS-5461 in major depressive disorder

March 7, 2014

Phase III results show brexpiprazole to be well tolerated as adjunctive therapy for MDD patients

March 7, 2014

Stemnion divulges new cell compositions for neurological disorders

March 7, 2014

New KOR-1 antagonists patented by the Scripps Research Institute

March 6, 2014

Novartis reports novel SMN modulators for spinal muscular atrophy

March 6, 2014

Eisai and Biogen Idec to collaborate in Alzheimer's disease

March 6, 2014

International Stem Cell reports interim data from stem cell primate study for Parkinson's disease

March 6, 2014

Janssen Pharmaceutica designs new agents for pain

March 6, 2014

FDA lifts clinical hold from Oxycyte development program

March 5, 2014

Forest Laboratories submits NDA for memantine and donepezil combination

March 5, 2014

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...